VRDN
Viridian Therapeutics, Inc.
$19.03
-0.53
(-2.71%)
Mkt Cap
2.16B
Volume
2,457,291
52W Range
13.18-34.29
Sector
Healthcare
Beta
0.96
EPS (TTM)
-3.66 USD
P/E Ratio
-9.37
Revenue (TTM)
71.13M USD
Rev Growth (5Y)
+132.2%
EPS Growth (5Y)
N/A
Company Description
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.85M | 302,000 | 314,000 | 1.77M | 2.96M | 1.05M | 4.46M | 8.39M | 4.00M | 3.34M | 2.54M | 4.32M |
| Net Income | (342.60M) | (269.95M) | (237.73M) | (129.87M) | (79.41M) | (110.72M) | (41.87M) | (32.70M) | (26.51M) | (12.67M) | (11.33M) | (7.89M) |
| EPS | -3.32 | -3.98 | -5.31 | -3.91 | -6.66 | -31.20 | -20.31 | -16.57 | -20.66 | -17.57 | -21.00 | -52.46 |
| Free Cash Flow | (276.89M) | (232.83M) | (185.07M) | (94.64M) | (54.92M) | (29.82M) | (36.14M) | (27.29M) | (28.41M) | (7.23M) | (7.02M) | (2.48M) |
| FCF / Share | -3.27 | -3.43 | -4.14 | -2.95 | -4.61 | -8.38 | -17.30 | -13.83 | -22.15 | -10.03 | -13.02 | -16.48 |
| Operating CF | (276.39M) | (232.32M) | (184.17M) | (93.84M) | (54.58M) | (29.78M) | (36.06M) | (26.84M) | (28.17M) | (7.23M) | (6.90M) | (2.21M) |
| Total Assets | 899.42M | 742.40M | 490.42M | 435.09M | 203.71M | 131.25M | 30.26M | 66.15M | 52.48M | 4.26M | 12.90M | 8.09M |
| Total Debt | 50.69M | 21.09M | 21.05M | 5.26M | 1.04M | 455,000 | 8.30M | 10.30M | 9.92M | 1.04M | 1.10M | 80,000 |
| Cash & Equiv | 212.38M | 99.59M | 102.83M | 155.58M | 42.30M | 45.90M | 24.85M | 32.61M | 47.44M | 3.34M | 10.83M | 5.12M |
| Book Value | 722.17M | 671.64M | 442.02M | 395.06M | 187.72M | 120.04M | 15.75M | 51.34M | 38.51M | (326,000) | 10.41M | 5.99M |
| Return on Equity | -0.47 | -0.40 | -0.54 | -0.33 | -0.42 | -0.92 | -2.66 | -0.64 | -0.69 | N/A | -1.09 | -1.32 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 284,000 | 141,000 | 132,000 | 70.57M | 75,000 | 72,000 | 72,000 | 86,000 | 72,000 | 72,000 | 72,000 | 72,000 |
| Net Income | (127.12M) | (104.90M) | (120.36M) | (34.60M) | (100.73M) | (86.91M) | (79.72M) | (76.69M) | (64.99M) | (48.54M) | (66.86M) | (47.66M) |
| EPS | -1.18 | -1.03 | -1.11 | -0.34 | -1.23 | -0.87 | -0.81 | -1.15 | -1.02 | -0.79 | -1.35 | -1.09 |
| Free Cash Flow | (106.63M) | (119.68M) | (23.99M) | (84.74M) | (75.42M) | (92.74M) | (73.45M) | (68.00M) | (46.16M) | (45.22M) | (38.05M) | (39.39M) |
| FCF / Share | -0.99 | -1.17 | -0.28 | -1.04 | -0.92 | -1.14 | -0.92 | -1.02 | -0.72 | -0.74 | -0.77 | -0.90 |
| Operating CF | (105.32M) | (119.65M) | (23.75M) | (84.61M) | (75.37M) | (92.65M) | (73.33M) | (67.71M) | (46.06M) | (45.22M) | (38.00M) | (38.98M) |
| Total Assets | 1.10B | 789.02M | 899.42M | 577.14M | 582.32M | 660.98M | 742.40M | 771.90M | 585.66M | 630.38M | 490.42M | 328.76M |
| Total Debt | 242.88M | 51.17M | 50.69M | 23.82M | 21.34M | 21.22M | 21.09M | 21.11M | 20.96M | 21.06M | 21.05M | 20.82M |
| Cash & Equiv | 164.99M | 176.35M | 212.38M | 169.65M | 117.32M | 116.22M | 99.59M | 200.32M | 107.67M | 91.64M | 102.83M | 111.60M |
| Book Value | 662.10M | 636.01M | 722.17M | 502.97M | 515.17M | 604.47M | 671.64M | 707.50M | 529.34M | 582.53M | 442.02M | 283.58M |
| Return on Equity | -0.19 | -0.16 | -0.17 | -0.07 | -0.20 | -0.14 | -0.12 | -0.11 | -0.12 | -0.08 | -0.15 | -0.17 |
VRDN News
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Now Rated “Moderate Buy” by Sell-Side Analysts
Viridian Therapeutics: Two Products, One Commercial Buildout
Viridian Intersects Over 50 Metres of Mineralization from Surface at Kraken Main
27,472 Shares in Viridian Therapeutics, Inc. $VRDN Acquired by Jupiter Topco LLC
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Algert Global LLC Sells 81,762 Shares of Viridian Therapeutics, Inc. $VRDN
Deutsche Bank AG Invests $8.87 Million in Viridian Therapeutics, Inc. $VRDN
Viridian Reports Continuation of Massive Sulphides at Kraken Main; First Assays Pending
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results